This site is intended for healthcare professionals

EMA validates MAA for valoctocogene roxaparvovec.

Read time: 1 mins
Last updated:28th Jul 2021
Published:16th Jul 2021
BioMarin Pharmaceutical Inc. announced that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe haemophilia A. With this validation the MAA review can now commence. A CHMP opinion is anticipated in the first half of 2022.
Condition: Haemophilia A
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest